TNFRSF8 and Hodgkins lymphoma: In accordance with the European Medicines Agency (EMA), BV is indicated for adult patients with previously untreated CD30+ Stage III or IV HL in combination with doxorubicin, vinblastine and dacarbazine (AVD); it is also available for the treatment of adult patients with CD30+ HL who are at increased risk of relapse or progression following autologous stem cell transplant and for adult patients with relapsed or refractory CD30+ HL.